| Document |
Document Title |
|
WO/2011/120925A1 |
The subject of the present invention for the treatment of endometriosis is the provision of a parenteral pharmaceutical form (release system) for the controlled release of an aromatase inhibitor (AI) with a daily release rate which does ...
|
|
WO/2011/123041A1 |
The outcome of an in vitro fertilization (IVF) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (HRG) gene or protein a...
|
|
WO/2011/120877A1 |
The present invention is concerned with aryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I, wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as V...
|
|
WO/2011/120071A1 |
Peptide analogues of oxytocin are described together with methods of treating conditions ameliorated by modulating oxytocin receptor. The peptide analogues are seleno or telluro peptide analogues. Methods of synthesis of selenocysteine, ...
|
|
WO/2011/115183A1 |
Disclosed is a monocyclic pyrimidine derivative. To be more specific, the pyrimidine derivative is effective in the prophylaxis and/or treatment of disorders associated with signal transmission mediated by Toll-like receptors (TLR).
|
|
WO/2011/114109A1 |
The invention provides cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f
]azulene-9-carbonyl)-2-fluoro-benzylamide para-toluenesulphonate, pharmaceutical compositions containing it, and its use in t...
|
|
WO/2011/115804A1 |
Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein di...
|
|
WO/2010/146407A9 |
The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositi...
|
|
WO/2011/111588A1 |
Provided are a method of inducing the differentiation of germline stem cells possessing the capabilities of self-regeneration and spermiogenesis from pluripotent stem cells such as iPS cells, a method of maintaining and expanding the ger...
|
|
WO/2011/111817A1 |
Disclosed is a compound which is useful as a therapeutic or prophylactic agent for diseases associated with 5-HT2C receptor, especially for urinary incontinence such as stress urinary incontinence, urge urinary incontinence and mixed uri...
|
|
WO/2011/112791A1 |
The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.
|
|
WO/2011/111714A1 |
Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R...
|
|
WO/2011/113065A2 |
The present invention provides polymers, compositions thereof, and polyplexes comprising said polymers. In particular, cationic polymers, pegylated versions thereof, and polynucleotide containing polyplexes comprising such polymers are p...
|
|
WO/2011/108711A1 |
Provided are: a model animal which closely models actual clinical cases of disorders such as pregnancy-induced hypertension syndrome; a method for producing said model animal; a screening method using said model animal to screen candidat...
|
|
WO/2011/057241A9 |
|
|
WO/2011/100983A1 |
Curcumin is a water insoluble component of turmeric, the yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use...
|
|
WO/2011/100984A1 |
Curcumin is a water insoluble component of turmeric, the yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use...
|
|
WO/2011/102684A2 |
The present invention relates to a composition containing placenta extracts as active ingredients. More particularly, placenta extracts which are natural substances extracted from placentas of livestock exhibit effects that can replace s...
|
|
WO/2011/099507A1 |
The purpose of the present invention is to improve the solubility of a 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)- 4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d] pyrimidine-5-carboxylic acid. Disclosed is a choline salt ...
|
|
WO/2011/098262A2 |
Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying antitumor agents are described. Furthermore, novel methods an...
|
|
WO/2011/099872A1 |
Methods for improving the functionality and/or fertility of sperm, for example, by enhancing motility and extending the lifespan of sperm in the female reproductive tract, by adding PEG to the surface of the sperm are provided. Such meth...
|
|
WO/2011/096490A1 |
Disclosed is a prophylactic and/or therapeutic agent for rejection after transplant surgery and for diseases caused by immune system abnormalities, comprising a compound represented by formula (I) or a pharmacologically acceptable salt t...
|
|
WO/2011/096462A1 |
Provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof as a novel compound having an NPY Y5 receptor antagonistic activity. In formula (I), R1, R2, and R3 each independently re...
|
|
WO/2011/096196A1 |
The present invention relates to the roles played by a LSD1 gene in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the LSD1 gene or a composition, vector or cell...
|
|
WO/2011/091890A1 |
The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.
|
|
WO/2011/091892A1 |
The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, between about 3 to about 5 days after unprotecte...
|
|
WO/2011/093599A2 |
The present invention relates to compositions containing yeast hydrolysate for prevention and improvement of disorders associated with menopause or post menopause, and a method for manufacturing the compositions. The compositions of the ...
|
|
WO/2011/091623A1 |
A functional nutriment with effects of promoting lactation and recovery for postpartum women containing marine proteins, papaya and calcium preparation. The functional nutriment also contains Seaweed powder, jujube powder, olive oil, cas...
|
|
WO/2011/091461A1 |
The present invention relates to a compound of general formula (III) for use in the treatment and/or prevention of diseases, in particular inflammatory diseases, which are related to eosinophile peroxidase, wherein R1 is CH2, NH, O, S or...
|
|
WO/2011/090062A1 |
Disclosed are a piperazine compound represented by formula (1) and a salt thereof. (In the formula, X represents CH or a N atom, R1 represents a C1-6 alkyl group; R2 represents any of a C1-6 alkyl group optionally having a substituted ba...
|
|
WO/2011/082488A1 |
This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
|
|
WO/2011/084668A1 |
The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with addition...
|
|
WO/2011/081173A1 |
A tetracyclic compound represented by formula (I) (wherein Q represents -O- or the like; X represents CH or the like; R1 represents a lower alkyl group or the like; R2 and R3 independently represent a hydrogen atom or the like; and R4 an...
|
|
WO/2011/077043A2 |
The invention relates to novel compounds having formula (I) and the cosmetic or pharmaceutical use thereof.
|
|
WO/2011/077800A1 |
A neutral fat level control agent, a cholesterol level control agent, a free fatty acid level control agent and an anti-obesity agent, each characterized by comprising at least one of protopanaxatriol, panaxatriol, protopanaxadiol and pa...
|
|
WO/2011/076117A1 |
The invention provides a composition comprising menopausal gonadotrophins, wherein the composition contains sucrose as stabilizer. The composition provided in the invention has enhanced stability.
|
|
WO/2011/075801A1 |
Described and disclosed is the use of cubebin, a dibenzylbutyrolactone lignan, of the semi-synthetic and synthetic derivatives thereof, and of other lignans and neolignans for the treatment of erectile dysfunction.
|
|
WO/2011/078102A1 |
Disclosed is a compound having an excellent DGAT-inhibiting activity and an excellent anti-feeding activity, or a pharmacologically acceptable salt thereof. Specifically disclosed is a compound represented by general formula (I) [wherein...
|
|
WO/2011/072509A1 |
A progesterone formulation composition and the preparation method thereof are disclosed. The composition is composed of progesterone oil content prepared from progesterone, non-polar solvents and solubilizers and encapsulating materials....
|
|
WO/2011/074992A1 |
The present invention relates to a medicament including a treatment composition in combination with at least one anti-inflammatory composition, characterised in that the treatment composition is extracted from whole milk, processed milk ...
|
|
WO/2011/069871A1 |
The invention provides a method for providing emergency contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate in an oral dosage form before, during or after a me...
|
|
WO/2011/067189A2 |
The invention relates to the treatment of endometriosis using cMet inhibitors, and medication comprising cMet inhibitors for treating endometriosis.
|
|
WO/2011/067302A1 |
The present invention is directed to a topical pharmaceutical composition which comprises a compound of formula (I), such as hydroxytyrosol, or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof, and a pharmaceuticall...
|
|
WO/2011/058766A1 |
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or –SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have block...
|
|
WO/2011/058943A1 |
Disclosed is a pharmaceutical composition formed from combining a compound having an MCH receptor antagonist activity or the pharmaceutically acceptable salt thereof or a solvate of said compound and salt with a compound having an NPY Y5...
|
|
WO/2011/057386A1 |
There is provided a novel topical composition, a novel prophylactic device, and a method of using them for stimulating and maintaining an erection of a sexual organ in a subject in need thereof. The topical composition, prophylactic devi...
|
|
WO/2011/058557A1 |
A method of treating or preventing an ovary-related syndrome associated with infertility in a subject in need thereof is provided. The method comprising administering to the subject a pharmaceutical composition comprising an active ingre...
|
|
WO/2011/055838A1 |
Disclosed are use and the like of a compound represented by formula (I), a salt thereof or a solvate thereof, for the purpose of inhibiting the biosynthesis of testosterone.
|
|
WO/2011/055550A1 |
Disclosed is a therapeutic agent for cellular immune diseases, which comprises a substance capable of inhibiting the binding between a Neuropilin-1/Plexin-A1 hetero receptor and Sema3A as an active ingredient. The substance is, for examp...
|
|
WO/2011/055917A2 |
The present invention relates to a composition for improving sexual function, comprising, as an active ingredient, at least one compound selected from a group consisting of arginine derivatives or the pharmaceutically acceptable salts th...
|
